These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9300692)

  • 1. Introduction of exogenous class II trans-activator in MHC class II-deficient ABI fibroblasts results in incomplete rescue of MHC class II antigen expression.
    Peijnenburg A; Gobin SJ; van Eggermond MC; Godthelp BC; van Graafeiland N; van den Elsen PJ
    J Immunol; 1997 Sep; 159(6):2720-7. PubMed ID: 9300692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
    Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
    J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity.
    Sartoris S; Valle MT; Barbaro AL; Tosi G; Cestari T; D'Agostino A; Megiovanni AM; Manca F; Accolla RS
    J Immunol; 1998 Jul; 161(2):814-20. PubMed ID: 9670958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.
    Sartoris S; Tosi G; De Lerma Barbaro A; Cestari T; Accolla RS
    Eur J Immunol; 1996 Oct; 26(10):2456-60. PubMed ID: 8898960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction of defective expression in MHC class II deficiency (bare lymphocyte syndrome) cells by retroviral transduction of CIITA.
    Bradley MB; Fernandez JM; Ungers G; Diaz-Barrientos T; Steimle V; Mach B; O'Reilly R; Lee JS
    J Immunol; 1997 Aug; 159(3):1086-95. PubMed ID: 9233601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells.
    Croce M; De Ambrosis A; Corrias MV; Pistoia V; Occhino M; Meazza R; Giron-Michel J; Azzarone B; Accolla RS; Ferrini S
    Oncogene; 2003 Oct; 22(49):7848-57. PubMed ID: 14586411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells.
    Rigaud G; De Lerma Barbaro A; Nicolis M; Cestari T; Ramarli D; Riviera AP; Accolla RS
    J Immunol; 1996 Jun; 156(11):4254-8. PubMed ID: 8666795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).
    Cycon KA; Rimsza LM; Murphy SP
    Exp Hematol; 2009 Feb; 37(2):184-194. PubMed ID: 19081173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.
    Xu Y; McDonald J; Perloff E; Butticè G; Schreiber BM; Smith BD
    Mol Immunol; 2007 Mar; 44(7):1709-21. PubMed ID: 16982097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant.
    Zhou H; Su HS; Zhang X; Douhan J; Glimcher LH
    J Immunol; 1997 May; 158(10):4741-9. PubMed ID: 9144488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two newly diagnosed HLA class II-deficient patients identified by rapid vector-based complementation analysis reveal discoordinate invariant chain expression levels.
    Schmetterer KG; Seidel MG; Körmöczi U; Rottal A; Schwarz K; Matthes-Martin S; Steinberger P; Pickl WF
    Int Arch Allergy Immunol; 2010; 152(4):390-400. PubMed ID: 20197681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-1 beta inhibits IFN-gamma-induced class II MHC expression by suppressing transcription of the class II transactivator gene.
    Rohn W; Tang LP; Dong Y; Benveniste EN
    J Immunol; 1999 Jan; 162(2):886-96. PubMed ID: 9916712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA).
    Takamura Y; Ikeda H; Kanaseki T; Toyota M; Tokino T; Imai K; Houkin K; Sato N
    Glia; 2004 Mar; 45(4):392-405. PubMed ID: 14966870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
    Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ
    Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain.
    Itoh-Lindstrom Y; Piskurich JF; Felix NJ; Wang Y; Brickey WJ; Platt JL; Koller BH; Ting JP
    J Immunol; 1999 Sep; 163(5):2425-31. PubMed ID: 10452977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting the specificity of the MHC class II transactivator CIITA in vivo.
    Otten LA; Leibundgut-Landmann S; Huarte J; Kos-Braun IC; Lavanchy C; Barras E; Borisch B; Steimle V; Acha-Orbea H; Reith W
    Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.
    Satoh A; Toyota M; Ikeda H; Morimoto Y; Akino K; Mita H; Suzuki H; Sasaki Y; Kanaseki T; Takamura Y; Soejima H; Urano T; Yanagihara K; Endo T; Hinoda Y; Fujita M; Hosokawa M; Sato N; Tokino T; Imai K
    Oncogene; 2004 Nov; 23(55):8876-86. PubMed ID: 15467734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class II transactivator promoter activity is suppressed through regulation by a trophoblast noncoding RNA.
    Geirsson A; Paliwal I; Lynch RJ; Bothwell AL; Hammond GL
    Transplantation; 2003 Jul; 76(2):387-94. PubMed ID: 12883198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.
    Souwer Y; Chamuleau ME; van de Loosdrecht AA; Tolosa E; Jorritsma T; Muris JJ; Dinnissen-van Poppel MJ; Snel SN; van de Corput L; Ossenkoppele GJ; Meijer CJ; Neefjes JJ; Marieke van Ham S
    Br J Haematol; 2009 May; 145(3):334-43. PubMed ID: 19245431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites.
    Arancibia-Cárcamo CV; Osawa H; Arnett HA; Háskova Z; George AJ; Ono SJ; Ting JP; Streilein JW
    Eur J Immunol; 2004 Feb; 34(2):471-80. PubMed ID: 14768052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.